Association between maternal urinary speciated arsenic concentrations and gestational diabetes in a cohort of Canadian women

Ashley‐Martin, Jillian; Dodds, Linda; Arbuckle, Tye E.; Bouchard, Maryse F.; Shapiro, Gabriel D.; Fisher, Mandy; Monnier, Patricia; Morisset, Anne‐Sophie; Ettinger, Adrienne S.

doi:10.1016/j.envint.2018.10.008

Cited by 41 publications

(52 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cohort study indicated that the Canadian women with urine levels of DMA 3.52 μg As/L have an increased risk of GDM (a odds ratio = 3.86; 95% confidence interval: 1. 18, 12.57;Ashley-Martin et al, 2018). Table 4 shows the epidemiological research on the associations between arsenic exposure and risk of diabetes.…”

Section: Data Analysis Of Nhanes III (2003 and 2004) Involving 1279mentioning

confidence: 99%

The role of arsenic in obesity and diabetes

Farkhondeh

Samarghandian

Azimi‐Nezhad

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

As many individuals worlwide are exposed to arsenic, it is necessary to unravel the role of arsenic in the risk of obesity and diabetes. Therefore, the present study reviewed the effects of arsenic exposure on the risk and potential etiologic mechanisms of obesity and diabetes. It has been suggested that inflammation, oxidative stress, and apoptosis contribute to the pathogenesis of arsenic‐induced diabetes and obesity. Though arsenic is known to cause diabetes through different mechanisms, the role of adipose tissue in diabetes is still unclear. This review exhibited the effects of arsenic on the metabolism and signaling pathways within adipose tissue (such as sirtuin 3 [SIRT3]‐ forkhead box O3 [FOXO3a], mitogen‐activated protein kinase [MAPK], phosphoinositide‐dependant kinase‐1 [PDK‐1], unfolded protein response, and C/EBP homologous protein [CHOP10]). Different types of adipokines involved in arsenic‐induced diabetes are yet to be elucidated. Arsenic exerts negative effects on the white adipose tissue by decreasing adipogenesis and enhancing lipolysis. Some epidemiological studies have shown that arsenic can promote obesity. Nevertheless, few studies have indicated that arsenic may induce lipodystrophy. Arsenic multifactorial effects include accelerating birth and postnatal weight gains, elevated body fat content, glucose intolerance, insulin resistance, and increased serum lipid profile. Arsenic also elevated cord blood and placental, as well as postnatal serum leptin levels. The data from human studies indicate an association between inorganic arsenic exposure and the risk of diabetes and obesity. However, the currently available evidence is insufficient to conclude that low‐moderate dose arsenic is associated with diabetes or obesity development. Therefore, more investigations are needed to determine biological mechanisms linking arsenic exposure to obesity and diabetes.

show abstract

Section: Data Analysis Of Nhanes III (2003 and 2004) Involving 1279mentioning

confidence: 99%

The role of arsenic in obesity and diabetes

Farkhondeh

Samarghandian

Azimi‐Nezhad

2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…43 Residual confounding of the gestational age-PFAA associations cannot be excluded. For instance a study from Canada reported that increases in maternal gestational weight gain (GWG), which increases with gestational age, were associated with elevated cord blood PFOS and PFOA concentrations 44 Inclusion of maternal weight gain as a covariate in the regression models did however not change the associations between gestational age and PFOA, PFNA and PFOS serum concentrations in exclusively nursed infants (Supporting Information, Table A8). Birth weight, which is associated with gestational age, may be another potential confounder through influence on distribution volume of infant PFAAs.…”

Section: Impact Of Duration Of Breastfeeding Gestational Age and Infmentioning

confidence: 99%

Perfluoroalkyl Acids (PFAAs) in Serum from 2–4-Month-Old Infants: Influence of Maternal Serum Concentration, Gestational Age, Breast-Feeding, and Contaminated Drinking Water

Gyllenhammar

Benskin

Sandblom

et al. 2018

Environ. Sci. Technol.

View full text Add to dashboard Cite

Little is known about factors influencing infant perfluorinated alkyl acid (PFAA) concentrations. Associations between serum PFAA concentrations in 2-4-month-old infants (n=101) and determinants were investigated by multiple linear regression and General Linear Model (GLM) analysis. In exclusively breastfed infants, maternal serum PFAA concentrations 3 weeks after delivery explained 13% (perfluoroundecanoic acid, PFUnDA) to 73% (perfluorohexane sulfonate, PFHxS) of infant PFAA concentration variation. Median infant/maternal ratios decreased with increasing PFAA carbon chain length from 2.8 for perfluoroheptanoic acid (PFHpA) and perfluorooctanoic acid (PFOA) to 0.53 for PFUnDA, and from 1.2 to 0.69 for PFHxS and perfluorooctane sulfonate (PFOS). Infant PFOA, perfluorononanoic acid (PFNA) and PFOS increased 0.7-1.2% per day of gestational age. Bottle-fed infants had 2 times lower mean concentrations of PFAAs, and a higher mean percentage of branched (%br) PFOS isomers, than exclusively breastfed infants. PFOA, PFNA and PFHxS increased 8-11% per week of exclusive breastfeeding. Infants living in an area receiving PFAA-contaminated drinking water had 3-fold higher mean perfluorobutane sulfonate (PFBS) and PFHxS concentrations, and higher mean %br PFHxS. Pre-and postnatal PFAA exposure significantly contribute to infant PFAA serum concentrations, depending on PFAA carbon-chain length. Moderately PFBS-and PFHxS-contaminated drinking water is an important indirect exposure source.

show abstract

“…The literature search identified 50 articles: among them, 10 met the inclusion criteria and the following characteristics were extracted [ 14 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ]. The main characteristics of the included studies are summarized in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Several studies have found an association between GDM and As levels in maternal blood, urine and meconium, supporting the possibility that a high level of As exposure might predispose to maternal GDM. However, the data obtained so far are quite inconsistent [ 14 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

Maternal Arsenic Exposure and Gestational Diabetes: A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a metabolic complication associated with adverse outcomes for mother and fetus. Arsenic (As) exposure has been suggested as a possible risk factor for its development. The aim of this meta-analysis was to provide a comprehensive overview of published evidence on the association between As and GDM. The systematic search from PubMed, MEDLINE, and Scopus was limited to full-length manuscripts published in peer-reviewed journals up to April 2020, identifying fifty articles. Ten studies met the inclusion criteria, nine for quantitative synthesis with a total of n = 1984 GDM cases. The overall pooled risk was 1.56 (95% Confidence Interval - CI = 1.23, 1.99) with moderate heterogeneity (χ2 = 21.95; I2% = 64). Several differences among the included studies that may account for heterogeneity were investigated. Stratification for exposure indicator confirmed a positive association for studies assessing urine As. A slightly higher risk was detected pooling studies based in Asia rather than in North America. Stratification for GDM diagnostic criteria showed higher risks when diagnosis was made according to the Canadian Diabetes Association (CDA-SOGC) or World Health Organization (WHO) criteria, whereas a lower risk was observed when adopting the American Diabetes Association (ADA) criteria. These results provide additional evidence for a possible association between As exposure and GDM, although the data need to be interpreted with caution due to heterogeneity.

show abstract

Association between maternal urinary speciated arsenic concentrations and gestational diabetes in a cohort of Canadian women

Cited by 41 publications

References 43 publications

The role of arsenic in obesity and diabetes

The role of arsenic in obesity and diabetes

Perfluoroalkyl Acids (PFAAs) in Serum from 2–4-Month-Old Infants: Influence of Maternal Serum Concentration, Gestational Age, Breast-Feeding, and Contaminated Drinking Water

Maternal Arsenic Exposure and Gestational Diabetes: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About